新藥LCC03，經自噬路徑阻斷前列腺癌細胞成長

Taipei Medical University Institutional Repository > 醫學院 > 臨床醫學研究所 > 博碩士論文 > Item 987654321/61170

請使用永久網址來引用或連結此文件: http://libir.tmu.edu.tw/handle/987654321/61170

題名:	新藥LCC03，經自噬路徑阻斷前列腺癌細胞成長 A novel therapeutic drug, LCC03 efficiently blocks prostate cancer growth through activation of autophagy pathway
作者:	坂貞儀 Saka, Teigi
貢獻者:	臨床醫學研究所陳冠州
關鍵詞:	自噬作用;去勢抗性前列腺癌:小分子藥物 castration-resistant prostate cancer;small molecule drug;autophagy
日期:	2016-07-07
上傳時間:	2021-11-27 17:01:37 (UTC+8)
摘要:	Background: Prostate cancer is one of the most frequently diagnosed noncutaneous malignancy among men worldwide. It was the sixth leading cause of cancer-related deaths among Taiwanese in 2014. Androgen deprivation therapy was the standard treatment for advanced prostate cancer. However, many patients develop metastatic castration resistance prostate cancer (mCRPC), and there is no curable treatment for this stage. Aim: The aim of this study was to investigate the anti-cancer effect and possible mechanism of a new compound LCC03 in prostate cancer. Methods: To determine the roles of LCC03 in regulation of cell survival, cell viability assay was conducted by WST-1 assay. After confirming that LCC03 did not have a significant apoptotic effect, we used flow cytometric analysis to observe the mechanism of LCC03, the effects on cell cycle distribution and apoptosis. To examine the effect of LCC03 on the induction of autophagy in AIPC cells, autophagy-related protein expression was determined by Western blotting; TEM assay was performed to further confirm that autophagy could be induced by LCC03. Finally, we used bioluminescence imaging to evaluate the anti-tumor potential of LCC03 on prostate cancer bone metastasis in vivo, and performed IHC staining to directly observe the status of the autophagic protein LC3B in xenograft models. Results: LCC03 effectively inhibited cell proliferation and induced cell cycle arrest of C4-2 and PC-3 AIPC prostate cancer lines at the range of 0.625-5μM. A massively increased expression of autophagy markers Beclin-1, ATG12-ATG5 conjugate and LC3B but not the apoptosis-related protein was observed in LCC03 treated prostate cancer cells. Autophagic vacuoles staining, as well as TEM assays confirmed the formation of LCC03-induced autophagosome. Moreover, intraperitoneal injection of LCC03 at a dose of 40 mg/kg of body weight significantly suppressed PC-3 tumor growth in mouse bone with no detectable toxicity. Conclusion: Our results provided the evidence indicating that LCC03 can be served as a novel therapeutic drug for CRPC through activation of autophagy pathway.
描述:	碩士指導教授：陳冠州委員：蒲永孝委員：彭瓊琦委員：廖俊厚
資料類型:	thesis
顯示於類別:	[臨床醫學研究所] 博碩士論文

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
index.html		0Kb	HTML	44	檢視/開啟

檢視Licence

在TMUIR中所有的資料項目都受到原著作權保護.

TAIR相關文章

資料載入中.....